Cargando…

Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study

Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauber, Brett, Mange, Brennan, Zhou, Mo, Chaudhuri, Shomesh, Benz, Heather L., Caldwell, Brittany, Ruiz, John P., Saha, Anindita, Ho, Martin, Christopher, Stephanie, Bardot, Dawn, Sheehan, Margaret, Donnelly, Anne, McLaughlin, Lauren, Gwinn, Katrina, Lo, Andrew, Sheldon, Murray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818008/
https://www.ncbi.nlm.nih.gov/pubmed/33521289
http://dx.doi.org/10.1177/2381468320978407
_version_ 1783638751326502912
author Hauber, Brett
Mange, Brennan
Zhou, Mo
Chaudhuri, Shomesh
Benz, Heather L.
Caldwell, Brittany
Ruiz, John P.
Saha, Anindita
Ho, Martin
Christopher, Stephanie
Bardot, Dawn
Sheehan, Margaret
Donnelly, Anne
McLaughlin, Lauren
Gwinn, Katrina
Lo, Andrew
Sheldon, Murray
author_facet Hauber, Brett
Mange, Brennan
Zhou, Mo
Chaudhuri, Shomesh
Benz, Heather L.
Caldwell, Brittany
Ruiz, John P.
Saha, Anindita
Ho, Martin
Christopher, Stephanie
Bardot, Dawn
Sheehan, Margaret
Donnelly, Anne
McLaughlin, Lauren
Gwinn, Katrina
Lo, Andrew
Sheldon, Murray
author_sort Hauber, Brett
collection PubMed
description Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. Methods. We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients’ risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in “on-time,” motor symptoms, pain, cognition, and pill burden. The survey elicited patients’ willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. Results. A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. Conclusions. PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices.
format Online
Article
Text
id pubmed-7818008
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-78180082021-01-28 Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study Hauber, Brett Mange, Brennan Zhou, Mo Chaudhuri, Shomesh Benz, Heather L. Caldwell, Brittany Ruiz, John P. Saha, Anindita Ho, Martin Christopher, Stephanie Bardot, Dawn Sheehan, Margaret Donnelly, Anne McLaughlin, Lauren Gwinn, Katrina Lo, Andrew Sheldon, Murray MDM Policy Pract Article Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. Methods. We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients’ risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in “on-time,” motor symptoms, pain, cognition, and pill burden. The survey elicited patients’ willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. Results. A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. Conclusions. PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices. SAGE Publications 2021-01-18 /pmc/articles/PMC7818008/ /pubmed/33521289 http://dx.doi.org/10.1177/2381468320978407 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Article
Hauber, Brett
Mange, Brennan
Zhou, Mo
Chaudhuri, Shomesh
Benz, Heather L.
Caldwell, Brittany
Ruiz, John P.
Saha, Anindita
Ho, Martin
Christopher, Stephanie
Bardot, Dawn
Sheehan, Margaret
Donnelly, Anne
McLaughlin, Lauren
Gwinn, Katrina
Lo, Andrew
Sheldon, Murray
Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
title Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
title_full Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
title_fullStr Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
title_full_unstemmed Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
title_short Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
title_sort parkinson’s patients’ tolerance for risk and willingness to wait for potential benefits of novel neurostimulation devices: a patient-centered threshold technique study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818008/
https://www.ncbi.nlm.nih.gov/pubmed/33521289
http://dx.doi.org/10.1177/2381468320978407
work_keys_str_mv AT hauberbrett parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT mangebrennan parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT zhoumo parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT chaudhurishomesh parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT benzheatherl parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT caldwellbrittany parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT ruizjohnp parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT sahaanindita parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT homartin parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT christopherstephanie parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT bardotdawn parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT sheehanmargaret parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT donnellyanne parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT mclaughlinlauren parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT gwinnkatrina parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT loandrew parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy
AT sheldonmurray parkinsonspatientstoleranceforriskandwillingnesstowaitforpotentialbenefitsofnovelneurostimulationdevicesapatientcenteredthresholdtechniquestudy